CNS Drugs

News CNS Drugs

• Evotec and PsychoGenics Enter into a Strategic Alliance to Provide Integrated CNS Drug Discovery Solutions

  Evotec AG announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. The two companies will work together in a seamless fashion to provide existing and new clients access to their compleme more

• to-BBB realizes €4M investment round

  to-BBB Holding BV has realized a first close of its Series-B investment round at €4Million. The company welcomes the Dutch Healthcare Investors of Jonghoud International BV and the Boston Life Science fund of the Industrial Bank of Taiwan Management Corporation (IBTM). The existing investors Aescap more

• Cenix BioScience establishes new R&D subsidiary in Flanders

  Cenix BioScience GmbH announced that it is growing its R&D operations by establishing a new subsidiary in Flanders, Belgium.The new subsidiary company, named Cenix BioScience BVBA, will be wholly owned by its Dresden-based parent, and will help accelerate the development of the company’s R&D capabil more

Publications CNS Drugs

• Applicability of a Blood–Brain Barrier Specific Artificial Membrane Permeability Assay at the Early Stage of Natural Product-Based CNS Drug Discovery

  While numerous natural products (NPs) possess activity on central nervous system (CNS) targets, there has been no analytical approach to effectively identify compounds with high brain penetration potential in complex mixtures at the early stage of drug discovery. To overcome this issue, the performa more

• Drug use in patients with dementia: a register-based study in the health region of Girona (Catalonia/Spain)

  Purpose To describe the pattern of drug consumption among patients with dementia in a geographically defined general population in Catalonia (Spain), and to determine its association with age, gender, type of dementia and severity indicators. Methods Cross-sectional study that included 1,894 cases o more

• Pharmacogenomics of Central Nervous System (CNS) Drugs

  Abstract Central nervous system (CNS) disorders represent a major problem of health in developed countries, with important consequences in disability and health economics. Recent findings in CNS genomics and pharmacogenomics suggest that the introduction of pharmacogenomic proced more

Market studies CNS Drugs

• Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

  GBI Research, the leading business intelligence provider, has released its latest research “Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market”, which provides insights into sleep disorders therapeutics sales and price forecasts until more

Websites CNS Drugs